Biopharma organizations across the development and commercialization continuum are often asked to make critical decisions before they have the benefit of a full external perspective. Questions around positioning, evidence strength, or differentiation do not always wait for the next scheduled advisory board.

Traditional advisory boards remain valuable. They offer direct clinician discussion and credible validation. But they require time, coordination, and investment, so they’re typically convened once or twice a year per brand, while strategic questions arise far more often.

Simulated advisory boards (SABs) bridge internal planning and live clinician engagement. Envision’s SABs are powered by the Posteros platform, using AI-driven simulation grounded in published evidence and clinical discourse to deliver structured clinician feedback within 5 to 10 business days, up to 70% faster than traditional advisory timelines, according to illustrative results for one type of simulation.

Used thoughtfully, SABs let teams test key questions, explore how clinicians may respond to new data or evolving strategy, and flag potential concerns before a live advisory session. They’re designed to complement traditional advisory boards in a hybrid model that pairs early simulation with direct clinician engagement.

This early testing can meaningfully shape how teams define endpoints, positioning, and value narratives, an impact illustrated later in this paper.

Download your copy below to explore the approach in more detail and see how simulated advisory boards can support faster, more informed strategic decision-making.


CONTENTS

How does the current advisory model fall short?

What is a simulated advisory board?

How does it work?

Strategic value beyond speed

Economic and strategic ROI

Where simulated advisory boards deliver the most value

Addressing common concerns

A smarter start to advisory planning

A hybrid approach to advisory insight